Nov 8 - 12, 2022

37th Annual SITC Annual Meeting

Alloplex’s abstract has been accepted for a poster presentation.

Abstract (632) – Clinical update from a Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients with Metastatic Solid Tumours and Haematologic Malignancies.

About SITC:

As the largest conference focused solely on cancer immunotherapy, the Society for Immunotherapy of Cancer (‘SITC’)’s annual meeting and pre-conference programs provides international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.